Solid Biosciences (NASDAQ: SGEN) and Seattle Genetics (NASDAQ:SGEN) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends.


This table compares Solid Biosciences and Seattle Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Solid Biosciences N/A N/A N/A
Seattle Genetics -7.75% -21.01% -17.56%

Analyst Recommendations

This is a summary of recent ratings and target prices for Solid Biosciences and Seattle Genetics, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Solid Biosciences 1 2 4 0 2.43
Seattle Genetics 0 7 9 0 2.56

Solid Biosciences presently has a consensus price target of $45.14, indicating a potential downside of 10.87%. Seattle Genetics has a consensus price target of $70.62, indicating a potential downside of 8.36%. Given Seattle Genetics’ stronger consensus rating and higher possible upside, analysts clearly believe Seattle Genetics is more favorable than Solid Biosciences.

Valuation & Earnings

This table compares Solid Biosciences and Seattle Genetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Solid Biosciences N/A N/A -$52.11 million ($2.88) -17.59
Seattle Genetics $482.25 million 25.37 -$125.53 million ($0.88) -87.57

Solid Biosciences has higher earnings, but lower revenue than Seattle Genetics. Seattle Genetics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

60.2% of Solid Biosciences shares are held by institutional investors. 33.8% of Seattle Genetics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Solid Biosciences Company Profile

Solid Biosciences Inc. engages in identifying and developing therapies for duchenne muscular dystrophy in the United States. Its lead product candidate includes SGT-001, a gene therapy that is in Phase I/II clinical trials to restore functional dystrophin protein expression in patients' muscles. The company's product candidates also comprise SB-001, a monoclonal antibody to reduce fibrosis and inflammation. In addition, it is developing soft wearable assistive devices that have functional and therapeutic benefits to DMD patients. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Seattle Genetics Company Profile

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.

Receive News & Ratings for Solid Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solid Biosciences and related companies with's FREE daily email newsletter.